The core therapeutic focus of this medication is generally relevant for women of reproductive potential. Jasmine is primarily used for managing pregnancy prevention, and can generally also be applied across two significant symptomatic domains.

The medicine helps manage conditions characterized by severe cyclical mood and physical symptoms, such as those seen in Premenstrual Dysphoric Disorder (PMDD), and may assist with addressing skin manifestations like moderate acne vulgaris. This combination of therapeutic uses is commonly used to help with fertility control, symptoms that interfere with daily functioning during the premenstrual phase, and is relevant for easing the burden of inflammatory and non-inflammatory acne lesions.

It may assist with maintaining a sense of stability during symptomatic periods by contributing to the easing of severe anxiety and irritability, and by supporting symptomatic management of the menstrual cycle.

---

Quick Fact: Supportive Management for Cyclical Discomfort and Skin Manifestations

This combination of uses may help ease the overall symptom load for patients seeking assistance with reproductive health, hormonal skin issues, or severe premenstrual distress.

Regulatory References

1. NIH DailyMed drug information

Who Can and Cannot Use Jasmine?

Eligibility for Jasmine (Drospirenone/Ethinyl Estradiol) is strictly defined by regulatory authorities based on contraindications and patient risk factors, primarily related to thromboembolism and specific organ function.

Contraindicated Populations

Jasmine is contraindicated (must not be used) in females with:

• Thrombotic Risk: A high risk of arterial or venous thrombotic diseases, including a history of deep vein thrombosis, stroke, or myocardial infarction. Use is prohibited for women aged 35 or older who smoke.
• Organ Impairment: Renal impairment, adrenal insufficiency, or hepatic impairment (including liver tumors or active liver disease).
• Cancer History: Known or suspected breast cancer or other estrogen- or progestin-sensitive cancer.

Age and Condition-Based Rules

Classification	Official Regulatory Status
Approved Population	Females of reproductive potential for contraception. For acne treatment, use is approved in post-menarcheal females aged 14 or older [FDA].
Pregnancy/Lactation	Contraindicated in pregnancy. Not recommended for use in nursing mothers [NIH].
Conditional Restriction	The medicine must be discontinued at least four weeks before and two weeks after major surgery or prolonged immobilization. It is contraindicated with migraine with aura or uncontrolled hypertension [EMA].

The interaction profile for Jasmine (Drospirenone/Ethinyl Estradiol) is structured by two primary pathways: hepatic metabolism and anti-mineralocorticoid activity, as established in regulatory documents.

The medicine is contraindicated for co-administration with Hepatitis C drug regimens containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, due to the potential for elevated liver enzymes. Similarly, use by females over 35 years of age who smoke is a contraindication due to a significantly increased risk of serious cardiovascular events.

Strong CYP3A4 Inducers, such as Rifampin or the herbal product St. John's Wort, may accelerate the metabolism of the contraceptive components, which can decrease the exposure of the medicine and necessitate the use of back-up contraception. Conversely, strong inhibitors of CYP3A4 (e.g., Ketoconazole) may increase the plasma concentrations of Drospirenone and Ethinyl Estradiol.

A major concern is the anti-mineralocorticoid activity of Drospirenone. Co-administration with Potassium-Elevating Drugs (e.g., ACE Inhibitors, Potassium-sparing diuretics, or NSAIDs) carries a risk of Hyperkalemia. The official regulatory constraint requires serum potassium to be monitored during the first cycle of treatment when these agents are co-administered. Furthermore, individuals with Renal Impairment, Hepatic Impairment, or Adrenal Insufficiency are formally contraindicated due to their predisposition to Hyperkalemia.

How Jasmine Works

The mechanism of action for Jasmine involves the coordinated activity of the progestin drospirenone and the estrogen ethinyl estradiol, primarily through hormonal modulation of specific regulatory pathways.

---

HPO Axis Suppression and Ovulation Inhibition

This core mechanism centers on the drug's effect on the hypothalamic-pituitary-ovarian (HPO) axis. The active hormones exert a negative feedback signal that suppresses the production and mid-cycle surge of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). Modifying these central signaling cascades prevents the timely maturation and release of an egg (ovulation), resulting in the inhibition of ovulation.

---

Uterine and Cervical Modulation

The progestin component, drospirenone, acts within the local reproductive system, influencing tissue structure and secretion viscosity. This activity increases the viscosity of the cervical mucus and alters the structure of the endometrium (uterine lining). These mechanistic changes create a localized environment that impedes sperm transit and is less receptive to potential implantation. These changes constitute a secondary mechanism affecting reproductive tract function.

---

Targeting Mineralocorticoid and Androgen Receptors

Drospirenone also engages other distinct receptor systems by acting as an antagonist at the mineralocorticoid and androgen receptors. Blocking the mineralocorticoid receptor leads to the modulation of fluid and electrolyte balance by promoting sodium and water excretion. Antagonism at the androgen receptor results in the dampening of androgen signaling, constituting a secondary pathway effect.

Jasmine is administered exclusively by the oral route as a fixed-dose, combined hormonal contraceptive tablet. The primary principle governing its use is a continuous 28-day cyclic regimen. This structured schedule requires the patient to take one tablet daily at the same time every day to maintain consistent hormone levels throughout the course of use.

---

The standard regimen involves two distinct phases within the 28-day pack. The first 21 days consist of active film-coated tablets, each containing 3 mg of drospirenone and 0.03 mg of ethinyl estradiol. These active tablets must be followed immediately by seven consecutive days of inert (placebo) tablets. The tablets must be taken in the order directed by the blister pack, and a new 28-day pack is started immediately after the last inert tablet, ensuring an unbroken continuation of the cycle.

Regarding administration conditions, the official labeling permits the tablet to be taken with or without food. Use is generally confined to women of reproductive potential, specifically beginning after menarche, and it is not indicated for use post-menopause. Official use protocols include specific instructions for managing absorption failure: if severe vomiting or diarrhea occurs within three to four hours of taking an active tablet, the event should be regarded as a missed tablet and handled according to the documented procedural rules for missed doses. Furthermore, administration is not indicated for women with moderate or severe renal or hepatic impairment, defining a specific population constraint on its use.

Research evidence / Overview of studies for Jasmine

Evidence for use in Preventing Pregnancy (Contraception)

The evidence for the use of Jasmine in preventing pregnancy has been gathered through large-scale, multi-center controlled trials, typically conducted over 6 to 13 months, as well as long-term observational studies. Researchers in these studies primarily focused on rates of pregnancy (measured using the Pearl Index) as the main outcome, and monitored how the medicine relates to cycle control, such as the occurrence of unscheduled bleeding. Studies reported pregnancy rates in the observed populations, and research describes patterns related to cycle regularity.

Evidence for use in Premenstrual Dysphoric Disorder (PMDD)

Research exploring the use for PMDD involved short-term randomized, double-blind, placebo-controlled trials. These studies examined outcomes related to severe cyclical mood and physical symptoms, using validated scales to monitor patterns related to functional impairment. Studies reported on changes measured during the study period for both the medication group and the placebo group. The research noted a measured reported change in symptoms in both groups.

Evidence for use in Moderate Acne Vulgaris

The evidence for use in moderate acne vulgaris has been gathered through intermediate-term (about six months) placebo-controlled trials. These studies focused on females of reproductive age with moderate facial acne. Researchers monitored the percent reduction in inflammatory and non-inflammatory lesion counts and the assessment of overall skin appearance using the Investigator’s Global Assessment (IGA) scale. Studies monitored differences in changes in total lesion counts between the medication and placebo groups over the six-month period.

Current Research Gaps and Uncertainties

A major gap is the limited information for long-term outcomes regarding PMDD and acne, as the core controlled research only covers intermediate or short-term follow-up durations. Comparative evidence is lacking for certain uses, meaning there are few head-to-head trials against all other available hormonal or non-hormonal options for PMDD and acne. Results apply only to the populations studied, meaning findings describing group patterns cannot be fully generalized to populations not extensively included in the original clinical research.

Key Studies & References

1. A combined oral contraceptive containing 3-mg drospirenone/20-μg ethinyl estradiol in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment
2. Efficacy and safety of combined ethinyl estradiol/ drospirenone oral contraceptives in the treatment of acne (Review)

Common questions about Jasmine (FAQ)

Q: How long does it take for Jasmine to start working according to research?

Official prescribing information indicates that contraceptive protection is not fully effective until the first seven consecutive days of active tablet administration are complete. Because of this, the use of a non-hormonal, back-up contraceptive method is advised during this initial seven-day period.

Q: What information is available about stopping Jasmine?

The patient information provided by regulatory agencies addresses what to expect when a person stops using the medicine. This information typically covers when the next bleed may occur and notes that the body's natural cycle is expected to return over time.

Q: How is Jasmine described as being different from other medicines in the same class?

Regulatory documents note that the progestin component, drospirenone, is structurally unique because it possesses anti-mineralocorticoid activity. This means it can modulate the body's fluid and electrolyte balance by promoting the excretion of sodium and water.

Q: What characteristics make Jasmine a unique option compared to alternatives?

The unique anti-mineralocorticoid activity of the drospirenone component means the medicine influences fluid and electrolyte balance in the body. Due to this specific action, official warnings are in place concerning the risk of hyperkalemia (high potassium levels) for patients with certain pre-existing health conditions.

Q: Are there long-term side effects associated with Jasmine use described in official labeling?

Official safety information indicates that the risk of serious blood clots (Venous Thromboembolism or VTE) is highest during the first year of use. The risk is also increased if a person re-initiates use after stopping the medicine for four weeks or more.

Q: Can Jasmine be taken with common over-the-counter pain relievers?

Regulatory documents warn that using this medicine with potassium-elevating drugs, which includes non-steroidal anti-inflammatory drugs (NSAIDs) found in some common over-the-counter pain relievers, may increase the risk of hyperkalemia (high potassium). Because of this known interaction, official prescribing guidelines require serum potassium levels to be monitored when these agents are co-administered.

Q: What is the difference between the brand name and the generic name for Jasmine?

Jasmine is the brand name of the medicine. The non-proprietary or generic name for the product is the combination of its two active ingredients: drospirenone and ethinyl estradiol.

Q: How is Jasmine described as potentially affecting blood test results?

The medicine may influence the results of some laboratory tests, including those related to liver function and metabolic parameters. Regulatory documents describe the potential for monitoring of blood glucose and lipid levels for women with pre-existing conditions like diabetes.

Q: Is there a generic version of Jasmine available?

Yes, official records confirm that a generic version of the medicine is approved and available. This generic product contains the same active ingredients: drospirenone and ethinyl estradiol.

Q: Do the side effects of Jasmine typically go away over time?

According to official product information, irregular bleeding or spotting is a common occurrence, particularly during the initial three months of use. The product information indicates that this effect is common during the initial three months, implying a period of adjustment.

Q: Is hair loss mentioned as a possible side effect of Jasmine?

Hair loss, also known as alopecia, is listed in the official patient information as an uncommon side effect.

Q: Does Jasmine cause changes in weight according to clinical studies?

Official safety information lists fluid retention and changes in body weight as an uncommon side effect.

Q: Can Jasmine affect mood or sleep patterns?

Official product information lists mood changes as an uncommon side effect. There is no specific mention of impacts on sleep patterns in the regulatory documents reviewed.

Q: Are there any specific foods or drinks that have a known interaction with Jasmine?

Yes, the official prescribing information notes a potential interaction with grapefruit or grapefruit juice. Consumption of grapefruit may cause the medicine’s concentration in the body to increase.

Q: Does alcohol have a known interaction with Jasmine?

Professional drug interaction databases classify the relationship between the ethinyl estradiol component and alcohol (ethanol) as a minor interaction.

Q: Is Jasmine considered a 'new' medicine or has it been available for a while?

The active ingredients and dosage form have been available for a substantial duration. For example, generic versions of the medicine have been approved by the FDA since at least 2010.

Q: Does Jasmine contain gluten or common allergens?

Official patient leaflets note that the product contains lactose, which is a consideration for individuals with known lactose intolerance.

Q: Is there information available on how Jasmine might affect the ability to drive?

The patient information leaflet addresses the use of the medicine while operating machinery or driving. It typically indicates that no effects on the ability to drive are expected.

Q: Are there different strengths of Jasmine available?

The active hormonal tablets are consistently provided in a single dose combination. This means there are no different active dosage strengths available for the medicine.

Q: Where can I find the official regulatory information about Jasmine?

Official regulatory information can be found in the Prescribing Information or Summary of Product Characteristics documents. These are published by government health authorities like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Storage and Disposal: Official Regulatory Information

Official regulatory guidelines for products containing Jasmine require specific handling and storage protocols to maintain stability. The product must be stored in a controlled environment, typically maintained at ambient temperatures, often stipulated below 25 C or 30 C. To preserve product integrity and documented shelf-life, the item must be protected from direct sunlight and moisture by keeping it in the original, tightly closed container.

For disposal of unused or expired product, the preferred method is utilizing community-based drug take-back programs. If such a program is unavailable, consumers are advised to mix the product with an undesirable substance (such as coffee grounds or kitty litter), seal the mixture in a bag or container, and place it in the household trash. Expired stock in clinical settings must be strictly segregated and handled according to biomedical waste regulations, which prohibit discharging into uncontrolled dumps.